Shares of specialty athletic retailer Foot Locker Inc. (NYSE: FL) slid over 6% during premarket hours on Friday after the company missed analysts’ estimates on revenue and earnings for the first quarter of 2019.
Total sales of $2.07 billion were up 2.6% compared to the same period last year. Excluding the impact of foreign exchange, sales grew 4.7%. Comparable-store sales increased 4.6% during the quarter.
GAAP net income improved to $172 million, or $1.52 per share, from $165 million, or $1.38 per share, in the prior-year period. Adjusted EPS was $1.53.
At quarter-end, merchandise inventories totaled $1.21 billion, up 0.1% from the prior-year period. In constant currency, inventory growth was 1.7%.
During the first quarter, Foot Locker opened 14 new stores, remodeled or relocated 13 stores, and closed 34 stores. As of May 4, 2019, the company operated 3,201 stores in 27 countries in North America, Europe, Asia, Australia, and New Zealand. There were also 119 franchised Foot Locker stores operating in the Middle East, as well as 10 franchised Runners Point stores in Germany.
Foot Locker expects full-year 2019 EPS to be up high-single digits based on the share repurchase activity to date.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Agentforce in focus as Salesforce (CRM) gets ready for Q3 2025 earnings
After delivering mixed results in the first half, Salesforce, Inc. (NYSE: CRM) looks poised to report strong numbers when it publishes third-quarter results next week. The Customer relationship management platform
What to look for when Dollar Tree (DLTR) reports Q3 2024 earnings
Shares of Dollar Tree, Inc. (NASDAQ: DLTR) rose over 5% on Monday. The stock has dropped 27% over the past three months. The discount store chain is scheduled to report
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training